|CUR -- Germany Stock|| |
EUR 0.96 0.012 1.26%
Mr. Scott V. Ogilvie is Independent Director of Neuralstem Inc. Mr. Ogilvie is currently the President of AFIN International Inc. a private equitybusiness advisory firm which he founded in 2006. Additionally Mr. Ogilvie has served as a partner of Wirthlin Worldwide International a private strategic advisory and MA firm since September 2011. Prior to December 31 2009 he was CEO of Gulf Enterprises International Ltd a company that brings strategic partners expertise and investment capital to the Middle East and North Africa. He held this position since August 2006. Mr. Ogilvie previously served as Chief Operating Officer of CIC Group Inc. an investment manager a position he held from 2001 to 2007. He began his career as a corporate and securities lawyer with Hill Farrer Burrill and has extensive public and private corporate management and board experience in finance real estate and technology companies. During the past 5 years Mr. Ogilvie has served on the board of directors of Innovative Card Technologies Inc. Preferred Voice Inc GenSpera Inc. and Research Solutions Inc. .
Age: 60 Director Since 2008
49 6027 40 900 51 http://www.curasan.de
Scott Ogilvie Latest Insider Activity
The company has return on total asset (ROA)
of (13.09) %
which means that it has lost $13.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (42.32) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 265 K in total debt with debt to equity ratio (D/E) of 2.6 implying the company greatly relies on financing operations through barroing. curasan AG has Current Ratio of 2.1 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
curasan AG develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. The company was founded in 1988 and is based in Kleinostheim, Germany. curasan AG operates under Biotechnology classification in Germany and traded on Frankfurt Stock Exchange. It employs 30 people.curasan AG (CUR) is traded on Frankfurt Stock Exchange in Germany. It is located in Lindigstrasse 4 and employs 30 people.
curasan AG Leadership Team
|William Oldaker, Independent Director|
|David Castaneda, IR Contact|
|Stanley Westreich, Independent Director|
|Karl Johe, Chairman of the Board, Chief Scientific Officer|
|Scott Ogilvie, Independent Director|
|Catherine Sohn, Director|
|Richard Garr, President CEO, General Counsel, Director|
|Richard Daly, President CEO|
|Sandford Smith, Director|
|Jonathan Jones, CFO|
Stock Performance Indicators
Macroaxis portfolio users are unresponsive in their opinion about investing in curasan AG. What is your take regarding investing in curasan AG? Are you bullish or bearish?
and pair trading evaluation for curasan AG and Fielmann AG
. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Check also Trending Equities
. Please also try Equity Analysis
module to research over 250,000 global equities including funds, stocks and etfs to find investment opportunities.